CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with good durability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the phase 1/2 CADENZA trial.

“We conclude that PVEK represents a potentially practice-changing paradigm for patients with the rare disease BPDCN,” said study author Naveen Pemmaraju, MD, of MD Anderson Cancer Center in Houston, Texas, during an oral abstract session at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. “One half of first-line patients treated with PVEK subsequently received stem cell transplant. PVEK treatment had a manageable safety profile, and infusion-related reactions and peripheral edema were resolved with supportive care. No capillary-leak syndrome was obs

See Full Page